Loo et al., 2003 - Google Patents
Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding siteLoo et al., 2003
View HTML- Document ID
- 10487457805312844358
- Author
- Loo T
- Bartlett M
- Clarke D
- Publication year
- Publication venue
- Journal of Biological Chemistry
External Links
Snippet
The human multidrug resistance P-glycoprotein (ABCB1) transports a broad range of structurally diverse compounds out of the cell. The transport cycle involves coupling of drug binding in the transmembrane domains with ATP hydrolysis. Compounds such as verapamil …
- 239000003814 drug 0 title abstract description 69
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loo et al. | Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein: direct evidence for the substrate-induced fit mechanism for drug binding | |
| Loo et al. | Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site | |
| Loo et al. | Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein | |
| Loo et al. | Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12 | |
| Loo et al. | The “LSGGQ” motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence | |
| Loo et al. | Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein | |
| Loo et al. | Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains | |
| Biswas et al. | Role of ATP on the interaction of α-crystallin with its substrates and its implications for the molecular chaperone function | |
| Loo et al. | Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers | |
| Schmidt et al. | Crystal structure of the human σ1 receptor | |
| Snyder et al. | Electrophysiological and biochemical evidence that DEG/ENaC cation channels are composed of nine subunits | |
| Loo et al. | Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites | |
| Loo et al. | Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate | |
| Denlinger et al. | Regulation of Inducible Nitric Oxide Synthase Expression by Macrophage Purinoreceptors and Calcium (∗) | |
| Loo et al. | P-glycoprotein: ASSOCIATIONS BETWEEN DOMAINS AND BETWEEN DOMAINS AND MOLECULAR CHAPERONES (∗) | |
| Shapiro et al. | Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6 | |
| Lee et al. | Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors | |
| Osawa et al. | Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/KChIP3 | |
| Noda et al. | Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice | |
| Bang et al. | Fas-and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction: a typical model for convergent signal transduction | |
| Jemth et al. | A frustrated binding interface for intrinsically disordered proteins | |
| Sato et al. | A conserved amino acid motif (RXGRR) in the Glut1 glucose transporter is an important determinant of membrane topology | |
| Ghosh et al. | Activation of Nuclear Factor of Activated T Cells in a Cyclosporin A-resistant Pathway (∗) | |
| Adams et al. | Paradoxical stimulation of a DEG/ENaC channel by amiloride | |
| Baxter et al. | Allosteric control in a metalloprotein dramatically alters function |